Understanding sleep-wake mechanisms and drug discovery

@article{EquihuaBentez2017UnderstandingSM,
  title={Understanding sleep-wake mechanisms and drug discovery},
  author={Ana Clementina Equihua-Ben{\'i}tez and Khalil Guzm{\'a}n-V{\'a}squez and Ren{\'e} Drucker-Col{\'i}n},
  journal={Expert Opinion on Drug Discovery},
  year={2017},
  volume={12},
  pages={643 - 657}
}
ABSTRACT Introduction: Although not discernible at first glance, sleep is a highly active and regulated brain state. Although we spend practically one third of our lifetimes in this stage, its importance is often taken for granted. Sleep loss can lead to disease, error and economic loss. Our understanding of how sleep is achieved has greatly advanced in recent years, and with that, the management of sleep disorders has improved. There is still room for improvement and recently many new… 

An Update on Assessment, Therapeutic Management, and Patents on Insomnia

A need for the determination of various critical viewpoints for the evaluation of insomnia along with various accessible alternatives for treatment is indicated, aimed at providing an update on various patents on dosage forms containing drugs for insomnia therapy.

Molecular mechanisms in Alzheimer's disease and the impact of physical exercise with advancements in therapeutic approaches

This review focuses on biochemical mechanisms in the neuron both at normal and AD state with relevance to the tau hypothesis, amyloid hypothesis, the risk factors influencing dementia, oxidative stress, and neuroinflammation altogether integrated with neurodegeneration.

Feasibility of Patient-Controlled Sleep with Dexmedetomidine in Treating Chronic Intractable Insomnia

Patient-Controlled Sleep with Dex might be a potential treatment for patients with chronic intractable insomnia, however, it is an off-label use, and the potential side effects of dexmedetomidine with long-term use needs further evaluation.

Hypnotics with novel modes of action

A range of new hypnotics which are being developed or have recently received market approval target the orexin/hypocretin system and should have less side effects in terms of drug–drug interactions with e.g. alcohol, less memory impairment and dependence potential compared to classical hypnotics.

The Mechanism of Compound Anshen Essential Oil in the Treatment of Insomnia Was Examined by Network Pharmacology

This study demonstrates the multicomponent, multitarget, and multichannel characteristics of Compound Anshen essential oil and provides a new therapeutic idea and method for further research on the mechanism of Compounds Anshenessential oil in the treatment of insomnia.

NSS_A_262991 1033..1042

Patient-Controlled Sleep (PCSL) for chronic intractable insomnia where the traditional analgesics in PCA were replaced with dexmedetomidine (Dex), an alpha-2 agonist widely used for premedication, sedation, anxiolysis and analgesia is developed.

References

SHOWING 1-10 OF 123 REFERENCES

Orexin receptor antagonists as therapeutic agents for insomnia

The role of Orexin and its receptors on the sleep-wake cycle and that of orexin antagonists in the treatment of insomnia are discussed.

The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.

Among DORAs evaluated clinically, suvorexant has pharmacokinetic properties engineered for a plasma half-life appropriate for rapid sleep onset and maintenance at low to moderate doses, and the preservation of cognitive performance and the ability to arouse to salient stimuli after DORA administration suggest further advantages over historical therapies.

Assessing the efficacy of melatonin to curtail benzodiazepine/Z drug abuse.

Management of narcolepsy

The treatment of narcolepsy has evolved recently with the widespread use of newer drugs, including modafinil for daytime sleepiness, newer antidepressants for cataplexy and γ-hydroxybutyrate (sodium oxybate) for both excessive daytimeSleepiness and catapLexy.

Ectopic Overexpression of Orexin Alters Sleep/Wakefulness States and Muscle Tone Regulation during REM Sleep in Mice

Sleep/wakefulness abnormalities in transgenic mice that exhibit widespread overexpression of a rat prepro-orexin transgene driven by a β-actin/cytomegalovirus hybrid promoter are reported, suggesting that endogenous orexinergic activity should be appropriately regulated for normal maintenance of sleep states.

Sleep: a health imperative.

The American Academy of Sleep Medicine and the Sleep Research Society have developed this statement to communicate to national health stakeholders the current knowledge which ties sufficient sleep and circadian alignment in adults to health.

[Pharmacological treatment of insomnia].

This article reviews the sleep promoting drugs and substances that can be used for treatment of chronic insomnia.

The hyperarousal model of insomnia: a review of the concept and its evidence.

Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications

The efficacy and safety of ramelteon in patients with chronic insomnia was initially confirmed in short-term placebo-controlled trials, and a 6-month placebo- controlled international study and a 1-year open-label study in the USA demonstrated that ramelTEon was effective and well tolerated.

The two‐process model of sleep regulation: a reappraisal

Sleep appears to have not only a short‐term, use‐dependent function; it also serves to enforce rest and fasting, thereby supporting the optimization of metabolic processes at the appropriate phase of the 24‐h cycle.
...